Compare DexCom, Inc. (DXCM) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lemonade Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Lemonade Inc trades at $46.46 (market cap $3.63B). The key difference: DexCom, Inc. is far larger — about 8.8× Lemonade Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Lemonade Inc for 27 Days on average.
| DXCM | LMND | |
|---|---|---|
Market Cap | $31.86B | $3.63B |
Volume | 3,607,070 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $92.34 | $96.57 |
52-Week Low | $54.84 | $43.91 |
Typical Hold Time | 62 Days | 27 Days |
Enterprise Value | $31.32B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Lemonade (LMND) trades at $46.91, up 0.17% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $738 million, and net losses narrowing to -$166 million. Recent news highlights expansion into new states and AI-driven efficiency gains, with management targeting EBITDA profitability by late 2026.
The outlook is mixed: growth and margin improvement offer upside, but persistent losses and high valuation multiples pose risks. Analysts are divided with a consensus price target of $67, suggesting potential upside if profitability targets are met. Key risks include execution on profitability and competitive pressures in the insurtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
